Although the sensitivity of anti-SSA/Ro antibody for primary SS diagnosis is approximately 80% and is not adequate for exclusion of primary SS [13], our data suggest that the evaluation of ANA only is insufficient, and that anti-SSA/Ro antibody testing should be added for primary SS screening in patients with PAH. This evidence concerns the gene BTG3 and synovial sarcoma.